ArticlePloS one2014
Therapeutic potential of thiazolidinedione-8 as an antibiofilm agent against Candida albicans.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Anandamide Targets Membrane Integrity in Non-Journal of fungi (Basel, Switzerland) · 2026Article
- Quorum quenching of phenolic compounds from Leptolyngbya spp. MACC 32 via downregulation of the periplasmic receptor LuxP in Vibrio harveyi: Hinting a putative mechanism.World journal of microbiology & biotechnology · 2025Article
- Thiazolidin-4-Ones as a Promising Scaffold in the Development of Antibiofilm Agents-A Review.International journal of molecular sciences · 2023Review
- Candida albicans antibiofilm molecules: analysis based on inhibition and eradication studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Potential Combinatory Effect of Cannabidiol and Triclosan Incorporated into Sustained Release Delivery System against Oral Candidiasis.Pharmaceutics · 2022Article
- Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.Microorganisms · 2022Review
- Propolis characterization and antimicrobial activities againstSaudi journal of biological sciences · 2022Review
- Anti-Biofilm Activity of Cannabigerol againstMicroorganisms · 2021Article
- Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.Probiotics and antimicrobial proteins · 2021Review
- Anti-Biofilm Activity of Cannabidiol againstMicroorganisms · 2021Article
- Microbial Interkingdom Biofilms and the Quest for Novel Therapeutic Strategies.Microorganisms · 2021Review
- Intestinal Infection ofFrontiers in microbiology · 2021Review
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells.Scientific reports · 2020Article
- Design and synthesis of new drugs inhibitors of Candida albicans hyphae and biofilm formation by upregulating the expression of TUP1 transcription repressor gene.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020Article
- Exposure of Streptococcus mutans and Streptococcus sanguinis to blue light in an oral biofilm model.Lasers in medical science · 2020Article
- Comparative Evaluation of Combinatory Interaction between Endocannabinoid System Compounds and Poly-L-lysine againstBioMed research international · 2020Article
- Cannabigerol Prevents Quorum Sensing and Biofilm Formation ofFrontiers in microbiology · 2020Article
- Review
- Influence of Thiazolidine-2,4-Dione Derivatives with Azolidine or Thiosemicarbazone Moieties onMolecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is known as a commensal microorganism but it is also the most common fungal pathogen in humans, causing both mucosal and systemic infections. Biofilm-associated C. albicans infections present clinically important features due to their high levels of resistance to traditional antifungal agents. Quorum sensing is closely associated with biofilm formation and increasing fungal pathogenicity. We investigated the ability of the novel bacterial quorum sensing quencher thiazolidinedione-8 (S-8) to inhibit the formation of, and eradication of mature C. albicans biofilms. In addition, the capability of S-8 to alter fungal adhesion to mammalian cells was checked. S-8 exhibited specific antibiofilm and antiadhesion activities against C. albicans, at four- to eightfold lower concentrations than the minimum inhibitory concentration (MIC). Using fluorescence microscopy, we observed that S-8 dose-dependently reduces C. albicans-GFP binding to RAW macrophages. S-8 at sub-MICs also interfered with fungal morphogenesis by inhibiting the yeast-to-hyphal form transition. In addition, the tested agent strongly affected fungal cell wall characteristics by modulating its hydrophobicity. We evaluated the molecular mode of S-8 antibiofilm and antiadhesion activities using real-time RT-PCR. The expression levels of genes associated with biofilm formation, adhesion and filamentation, HWP1, ALS3 and EAP1, respectively, were dose-dependently downregulated by S-8. Transcript levels of UME6, responsible for long-term hyphal maintenance, were also significantly decreased by the tested agent. Both signaling pathways of hyphal formation-cAMP-PKA and MAPK-were interrupted by S-8. Their upstream general regulator RAS1 was markedly suppressed by S-8. In addition, the expression levels of MAPK cascade components CST20, HST7 and CPH1 were downregulated by S-8. Finally, transcriptional repressors of filament formation, TUP1 and NRG1, were dramatically upregulated by our compound. Our results indicate that S-8 holds a novel antibiofilm therapeutic mean in the treatment and prevention of biofilm-associated C. albicans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.